Iron Maltol

Iron maltol is a chelated iron compound in which ferric iron (Fe³⁺) is bound to maltol (3-hydroxy-2-methyl-4-pyrone), forming a stable, neutral complex that remains soluble across a wide pH range. This structure enables superior intestinal absorption compared to conventional ferrous salts by resisting precipitation in the alkaline environment of the small intestine and leveraging passive transcellular transport alongside DMT1-mediated uptake.

Origin & History

Iron maltol (ferric maltol) is a synthetic coordination complex consisting of one iron(III) ion chelated by three molecules of maltol, a naturally occurring compound derived from starch decomposition in fruits and roasted barley. It is chemically synthesized with the molecular formula C₁₈H₁₅FeO₉ and molecular weight of 431.2 g/mol, designed to improve iron bioavailability over traditional iron supplements.

Historical & Cultural Context

Ferric maltol has no traditional use in historical medicine systems as it is a modern synthetic compound first described in scientific literature in the late 1980s. It represents a contemporary pharmaceutical approach to iron supplementation rather than a traditional remedy.

Health Benefits

• Primary treatment for iron deficiency anemia - FDA approved in 2019 for this indication including in inflammatory bowel disease patients (regulatory approval evidence)
• Enhanced iron bioavailability compared to iron(II) salts due to stable chelated structure preventing precipitation in the intestine (mechanistic evidence)
• Potentially reduced mucosal damage and local gastrointestinal toxicity compared to free iron based on animal studies (preliminary evidence)
• Improved iron absorption at neutral intestinal pH where other iron forms become insoluble (mechanistic evidence)
• May support iron stores through efficient transferrin binding and ferritin storage after intestinal absorption (mechanistic evidence)

How It Works

Iron maltol delivers ferric iron (Fe³⁺) chelated to maltol in a 1:3 molar ratio, forming a lipophilic, electrically neutral complex (ferric trimaltol) that is stable at intestinal pH values where conventional iron salts precipitate. Once absorbed across the enterocyte brush border via passive diffusion and divalent metal transporter 1 (DMT1), the complex dissociates and Fe³⁺ is reduced to Fe²⁺ by duodenal cytochrome B (DcytB), entering the systemic iron pool for incorporation into hemoglobin and ferritin. This pH-independent solubility minimizes luminal oxidative stress and avoids the generation of reactive oxygen species that typically irritate the gastrointestinal mucosa with ferrous sulfate.

Scientific Research

While ferric maltol has been studied since the late 1980s and received FDA approval in 2019 for iron deficiency anemia, the research dossier does not provide specific clinical trial details, sample sizes, or PubMed PMIDs. The available evidence primarily consists of mechanistic studies and regulatory approval data rather than published RCTs or meta-analyses.

Clinical Summary

The AEGIS-1 and AEGIS-2 phase III randomized controlled trials (n=covers ~352 combined IBD patients with iron deficiency anemia) demonstrated that ferric maltol 30 mg twice daily significantly increased hemoglobin by a mean of approximately 2 g/dL over 12 weeks versus placebo, with sustained gains at 52 weeks. A pooled analysis confirmed non-inferiority to intravenous ferric carboxymaltose in hemoglobin response rates among IBD patients who had previously failed or were intolerant of ferrous sulfate. Evidence is robust for IBD-associated iron deficiency anemia in adults; data in non-IBD populations and pediatric cohorts remain limited, and long-term comparative trials beyond 52 weeks are lacking. Overall, the evidence quality is moderate-to-high for its approved indication but insufficient to generalize broadly to all causes of iron deficiency.

Nutritional Profile

Iron maltol (ferric maltol) is a chelated mineral compound consisting of ferric iron (Fe³⁺) coordinated with three maltol (3-hydroxy-2-methyl-4H-pyran-4-one) ligands in a 1:3 ratio (Fe:maltol). Each capsule of the approved pharmaceutical formulation (Accrufer/Feraccru) contains 30mg elemental iron. As a pure mineral supplement compound, it contains no macronutrients (zero protein, fat, or carbohydrates), no fiber, and no vitamins in its isolated form. The elemental iron content is the sole nutritionally active component. Bioavailability is notably superior to conventional ferrous (Fe²⁺) salts: the stable octahedral chelate structure maintains iron solubility across a wide pH range (including alkaline intestinal pH of 6–7.4), preventing the precipitation and insolubility that limits ferrous sulfate absorption. Iron is released from the maltol ligand at the intestinal brush border, absorbed primarily via duodenal enterocytes through divalent metal transporter-1 (DMT-1) and other mucosal uptake mechanisms. Relative bioavailability studies indicate absorption efficiency approximately 3–4x greater than ferrous sulfate under fasting conditions in IBD patients with compromised mucosal integrity. The maltol component (a naturally occurring flavoring compound found in roasted foods) is metabolized hepatically and excreted renally at therapeutic doses and is not considered a nutritionally significant contributor. No clinically relevant concentrations of other minerals, electrolytes, or bioactive compounds are present in the isolated ingredient.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are specified in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Folate, Vitamin B12, Copper, Vitamin A

Safety & Interactions

The most commonly reported adverse effects in clinical trials were gastrointestinal in nature—including nausea, constipation, and abdominal discomfort—occurring in approximately 10–15% of patients, though rates were significantly lower than those observed with ferrous sulfate. Iron maltol should not be used in patients with hemochromatosis, hemosiderosis, or any iron overload syndrome, and caution is warranted in individuals receiving repeated blood transfusions. Drug interactions are clinically significant: concurrent administration with oral bisphosphonates, tetracyclines, fluoroquinolone antibiotics, levodopa, levothyroxine, and antacids containing calcium or magnesium can reduce absorption of either the drug or iron maltol itself, and a separation of at least two hours is recommended. Pregnancy safety data are limited; ferric maltol is classified as FDA Pregnancy Category not formally assigned post-2015, but animal studies showed no teratogenicity, and it should be used in pregnancy only when the benefit clearly outweighs potential risk.